Dexcel Pharma Technologies Ltd. Roivant Sciences Ltd. (ROIV) insider trading activity

Dexcel Pharma Technologies Ltd. is > 10% Shareholder of Roivant Sciences Ltd.. Currently has a direct ownership of 103 Million shares of ROIV, which is worth approximately $1.11 Billion. The most recent transaction as insider was on Nov 10, 2022, when has been sold 4,000,000 shares (Common Shares) at a price of $5.0 per share, resulting in proceeds of $20,000,000. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 103M

0% 3M change

0% 12M change

Total Value Held $1.11 Billion

Dexcel Pharma Technologies Ltd. Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 10 2022	BUY Open market or private purchase	$20,000,000 $5.0 p/Share	4,000,000 Added 3.74%	102,849,443 Common Shares
Apr 25 2022	BUY Open market or private purchase	$33,626 $3.91 p/Share	8,600 Added 0.01%	98,849,443 Common Shares
Apr 22 2022	BUY Open market or private purchase	$121,354 $3.83 p/Share	31,685 Added 0.03%	98,840,843 Common Shares

Also insider at

PLX

Protalix BioTherapeutics, Inc. Healthcare

> 10% Shareholder

DPT